Navigation Links
Consumer Groups Will Continue to Press Stem Cell Patent Challenge
Date:2/28/2008

SANTA MONICA, Calif., Feb. 28 /PRNewswire-USNewswire/ -- Two consumer groups said today that they will continue their challenge of three overreaching patents on human stem cells held by the Wisconsin Alumni Research Foundation (WARF) despite a non-final decision by Patent Office allowing three amended claims in one of the disputed patents.

The Foundation For Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation (PUBPAT) said they would appeal any later final decision by the examiner supporting the claims to the Patent and Trademark Office's Board of Appeals, which frequently overturns the decision made by examiners. The groups also have the right to appeal any decision of that board to the U.S. Circuit Court for the Federal Circuit, if necessary.

The "non-final office decision" in the inter partes re-examination of the '913 patent was posted late Wednesday on the PTO's website.

"We won the first round when the PTO rejected all claims of the '780, '806 and '913 patents," said John M. Simpson, FTCR Stem Cell Project Director. "Now WARF has won the second round with respect to just one of the patents, but the battle is hardly over. We're in this for the long haul."

"The examiner based his decision on his own belief that it would not have been obvious to isolate human stem cells using widely known methods to isolate mouse stem cells, which contradicts the sworn testimony that we provided of four renowned stem cell embryologists who were doing such work", said Dan Ravicher, PUBPAT Executive Director. "Thus, the examiner took his own opinion over the opinions of our four leading stem cell scientist witnesses."

Joining the two consumer groups in the challenge from the beginning was Dr. Jeanne Loring, now of the Scripps Institute. After the initial rejection, Dr. Alan Trounson, then of Australia's Monash University and now president of the California Institute for Regenerative Medicine, Dr. Douglas Melton of Harvard and Dr. Chad Cowan of Harvard filed affidavits supporting the challenge.

The two groups noted that the patent challenge has already improved the situation for stem cell researchers; shortly after the PTO announced it would re-examine the three patents, WARF announced a substantial easing of its licensing requirements.

"WARF executives were acting like arrogant bullies blinded by dollar signs," said Simpson. "Our challenge has engendered a more co-operative stance on their part."

Decisions are pending on the other two patents. No other country recognizes the three WARF patents.

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at: http://www.ConsumerWatchdog.org.

The Public Patent Foundation is a not-for-profit legal services organization that represents the public's interests against the harms caused by the patent system, particularly the harms caused by wrongly issued patents and unsound patent policy. For more information, visit us on the web at http://www.pubpat.org.


'/>"/>
SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eyes on Puerto Rico: Johnson & Johnson Markets New Contact Lenses Directly to Consumers
2. Health and Fashion - Dow Corning Predicts the Top Trends Driving Consumers to the Beauty Counters
3. Weight Watchers to Present at Bank of America 2008 Consumer Conference
4. Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS 08
5. Microsoft to Showcase Innovative Solutions for Healthcare Providers and Consumers at HIMSS 2008 Annual Conference & Exhibition
6. Consumer Group Welcomes Introduction of Stem Cell Agency Oversight Bill
7. Men Are Vein Too: Innovative Treatment Sparks Unexpected Consumer Trend
8. Clarity for Consumers on Botox Complication and Death Reports
9. IHF Says Google Personal Health-Records System Gives Consumers Greater Control Over Privacy than HIPAA Rules
10. Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery
11. Wyeth Consumer Healthcare Names New Head of Global R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Donna Parker, L. ... she has not found any of them to be very practical. She wanted to ... and easily make changes in their health. It prompted her in writing “ A ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Learning to Use ... navigate life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is ... various nonprofits, former Chairman of the Board of Directors for CONTACT USA, and former ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: